NCI-2021-14390

A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor Positive (HR), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

This is a study that will test a new treatment for premenopausal women with Hormone Receptor positive HER-2 negative breast cancer. The treatment combines a medicine called TOL2506 with another treatment called endocrine therapy. TOL2506 is a type of medicine that can stop the ovaries from making hormones. The study will see if using TOL2506 along with endocrine therapy can help stop the cancer from growing. The study will be done with premenopausal women who have already been diagnosed with this type of breast cancer.

Hormone Receptor Positive HER-2 Negative: It is a type of breast cancer where the cancer cells rely on hormones, such as estrogen and progesterone, to grow, but they don't have an overactive HER2 receptor.

Endocrine Therapy: Endocrine therapy is a type of treatment for certain hormone-related conditions, like some types of breast or prostate cancer. It works by either blocking the body's production of hormones or interfering with how hormones attach to their respective receptors on cells. In the context of cancer, it's often used to prevent cancer cells from getting the hormones they need to grow, helping to slow down or stop the cancer's progression.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04906395

NCI-2021-14390

Clinical Trial Site: Einstein

To see all available clinical trials click here.